Clark Capital Management Group, Inc.
Position in LGND — Ligand Pharmaceuticals Inc
CIK 1352187
PHILADELPHIA, PA
Position in LGND
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$10,414,533
-$7,595,094 QoQ
Shares Held
32,948
-63.5% QoQ
Ownership
0.165%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#85
of 415 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Clark Capital Management Group, Inc. holds $136,817,304 across 5 Biotechnology names. LGND ranks #4 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
1,663,003 | $93,244,578 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
231,956 | $18,155,196 | |
| 3 | EXEL |
Exelixis, Inc.
|
271,878 | $14,792,881 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
This page
|
32,948 | $10,414,533 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
423 | $210,116 |
All Filings in LGND
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,414,533 | 32,948 | Shares | Sole | 2026-08-11 | |
| 2026-03-31 | $18,009,627 | 90,206 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,083,626 | 79,778 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $14,701,025 | 82,991 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,086,399 | 71,133 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,631,837 | 44,054 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,994,230 | 37,277 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $2,584,423 | 25,821 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||